RenovoRx regains Nasdaq compliance after $17.2M fundraising; hearing cancelled

RenovoRx, Inc.

Nasdaq confirmed RenovoRx met $2.5M minimum stockholders' equity requirement; prior deficiency remedied.
Company raised $17.2M in gross proceeds in 2024, extending cash runway into 2026.
Hearing before Nasdaq Hearings Panel cancelled; no ongoing monitor required.
Management to focus on Phase III TIGeR-PaC trial progress, TAMP pipeline expansion, and business development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.